KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EBITDA (2016 - 2025)

Historic EBITDA for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to $28.4 million.

  • Rigel Pharmaceuticals' EBITDA rose 10219.12% to $28.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.0 million, marking a year-over-year increase of 115172.05%. This contributed to the annual value of $24.2 million for FY2024, which is 21806.16% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported EBITDA of $28.4 million as of Q3 2025, which was up 10219.12% from $61.1 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' EBITDA ranged from a high of $61.1 million in Q2 2025 and a low of -$26.3 million during Q1 2022
  • Over the past 5 years, Rigel Pharmaceuticals' median EBITDA value was -$4.5 million (recorded in 2023), while the average stood at $2.0 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' EBITDA plummeted by 16289.31% in 2022, and later soared by 1356957.49% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' EBITDA (Quarter) stood at -$21.4 million in 2021, then skyrocketed by 109.71% to $2.1 million in 2022, then decreased by 5.44% to $2.0 million in 2023, then surged by 747.15% to $16.7 million in 2024, then surged by 70.64% to $28.4 million in 2025.
  • Its last three reported values are $28.4 million in Q3 2025, $61.1 million for Q2 2025, and $12.8 million during Q1 2025.